🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆ Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines ◆ Trump’s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.-Irish Trade Implications ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆ Markets Surge as August Opens: $400B Big Pharma Merger Speculation & AstraZeneca Deal Talks Grab Global Headlines ◆ Trump’s September Visit to Ireland: Agenda, Economic Policy Evaluation & U.S.-Irish Trade Implications ◆
Updated 12 Aug 2026 · ClinicalTrials.gov

Clinical Trials in Guangzhou

← All China trials

Every active and recruiting clinical study with an investigative site in China — searchable by condition, sponsor, phase and location. Refreshed daily from the ClinicalTrials.gov registry.

20
Recruiting now
30
Active studies
Starting soon Phase 2
Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)
Breast Cancer
Sun Yat-sen University · started 2026-11-04
📍 Guangzhou
NCT07255612 on ClinicalTrials.gov ↗
Starting soon Phase 1/Phase 2
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS Mutation
Genfleet Therapeutics (Shanghai) Inc. · started 2026-09
📍 Beijing · Guangzhou · Harbin · Zhengzhou · Wuhan · Shenyang
NCT07678593 on ClinicalTrials.gov ↗
Active
Development and Validation of an AI Foundation Model for Frozen-Section Pathology
Cancer, Intraoperative Pathology, Artificial Intelligence (AI)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · started 2026-04-27
📍 Guangzhou
NCT07708207 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Plaque Psoriasis
Bristol-Myers Squibb · started 2025-12-03
📍 Beijing · Guangzhou · Shenzhen · Handan · Zhengzhou · Changsha
NCT06979453 on ClinicalTrials.gov ↗
Active Phase 2
A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SHR-1139 in Patients With Moderate-to-severe Active Ulcerative Colitis
Adult Patients With Moderately to Severely Active Ulcerative Colitis
Guangdong Hengrui Pharmaceutical Co., Ltd · started 2025-12-01
📍 Guangzhou
NCT07232576 on ClinicalTrials.gov ↗
Recruiting Phase 2
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Alexion Pharmaceuticals, Inc. · started 2025-11-26
📍 Baotou · Beijing · Guangzhou · Hangzhou · Nanchang · Shenzhen
NCT07160608 on ClinicalTrials.gov ↗
Recruiting Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Plaque Psoriasis
Bristol-Myers Squibb · started 2025-09-22
📍 Bengbu · Beijing · Chongqing · Fuzhou · Guangzhou · Shenzhen
NCT07116967 on ClinicalTrials.gov ↗
Active Phase 2
A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B
Chronic Hepatitis B
Shanghai Argo Biopharmaceutical Co., Ltd. · started 2025-09-02
📍 Hefei · Beijing · Sichuan · Chongqing · Fuzhou · Guangzhou
NCT07135349 on ClinicalTrials.gov ↗
Recruiting Phase 1/Phase 2
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Nasopharyngeal Cancinoma (NPC), Recurrent Nasopharynx Carcinoma, Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University · started 2025-07-09
📍 Guangzhou
NCT06802835 on ClinicalTrials.gov ↗
Recruiting
The Real-world Study of AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)
Resectable Hepatocellular Carcinoma With High Risk of Recurrence
Sun Yat-sen University · started 2025-07-05
📍 Guangzhou
NCT07064681 on ClinicalTrials.gov ↗
Recruiting Phase 3
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
Sun Yat-Sen University Cancer Center · started 2025-05-04
📍 Fuzhou · Dongguan · Foshan · Guangzhou · Zhongshan · Nanning
NCT06749899 on ClinicalTrials.gov ↗
Recruiting Phase 3
Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines
Moderate to Severe Glabellar Lines
JHM BioPharma (Tonghua) Co. , Ltd. · started 2025-04-30
📍 Beijing · Chongqing · Guangzhou · Shijiazhuang · Changsha · Xuzhou
NCT06937944 on ClinicalTrials.gov ↗
Recruiting Phase 2
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）
Lung Cancer (NSCLC)
Sun Yat-sen University · started 2025-04-20
📍 Guangzhou
NCT06924398 on ClinicalTrials.gov ↗
Recruiting Phase 2/Phase 3
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)
Institute of Hematology & Blood Diseases Hospital, China · started 2025-03-03
📍 Hefei · Chongqing · Fuzhou · Guangzhou · Nanning · Guiyang
NCT06882057 on ClinicalTrials.gov ↗
Recruiting Phase 3
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Heart Failure, Heart Failure With Reduced Ejection Fraction
Cytokinetics · started 2024-12-19
📍 Beijing · Lanzhou · Guangzhou · Shenzhen · Luoyang · Changsha
NCT06736574 on ClinicalTrials.gov ↗
Recruiting
Long-term Follow-up Study of BRL-101 for TDT
Thalassemia, Beta
Bioray Laboratories · started 2024-12-08
📍 Guangzhou · Shenzhen · Nanning · Changsha · Tianjin · Guangxi
NCT06298630 on ClinicalTrials.gov ↗
Recruiting Phase 2
Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients
Post-stroke Cognitive Impairment
Simcere Pharmaceutical Co., Ltd · started 2024-04-08
📍 Fuyang · Hefei · Huangshan City · Guangzhou · Wuzhou · Shijiazhuang
NCT06315231 on ClinicalTrials.gov ↗
Recruiting Phase 4
Early Lumbar Drainage Plus Intrathecal Urokinase in Severe Aneurysmal Subarachnoid Hemorrhage (LD-ITUK)
Aneurysmal Subarachnoid Hemorrhage
Second Affiliated Hospital of Nanchang University · started 2024-03-28
📍 Hefei · Heihe · Fuzhou · Guangzhou · Harbin · Zhengzhou
NCT06284642 on ClinicalTrials.gov ↗
Recruiting
Early Warning and Intervention Mechanism of Foot Health Risk in Children and Adolescents
Flexible Flatfoot
Nanfang Hospital, Southern Medical University · started 2024-01-01
📍 Guangzhou
NCT06581978 on ClinicalTrials.gov ↗
Recruiting
Safety and Efficacy of Two-step Radical Prostatectomy
Prostate Cancer
Sun Yat-sen University · started 2023-02-15
📍 Guangzhou
NCT05722392 on ClinicalTrials.gov ↗
Recruiting
Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)
Acute Aortic Syndrome, Aortic Dissection Type a
Nanjing Medical University · started 2022-07-01
📍 Bengbu · Guangzhou · Nanjing · Yangzhou · Jinan · Chengdu
NCT05339529 on ClinicalTrials.gov ↗
Recruiting
Research on Potential Biomarkers of Prediabetes and Diabetes Based on MALDI-TOF MS Platform.
Prediabetes, Diabetes Mellitus, Gestational Diabetes Mellitus, Proteomics
Zhujiang Hospital · started 2022-05-20
📍 Guangzhou
NCT06097065 on ClinicalTrials.gov ↗
Recruiting
A Prospective Cohort Study On Change of Cognitive Function In Aged-related Hearing Loss With Hearing Aids
Age-related Hearing Loss, Hearing Loss, Sensorineural, Hearing Aid, Cognitive Function Abnormal
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · started 2022-03-09
📍 Guangzhou
NCT05694039 on ClinicalTrials.gov ↗
By invitation Phase 3
A Study to Test the Safety and Tolerability of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures
Stereotypical Prolonged Seizures
UCB Biopharma SRL · started 2022-02-03
📍 Beijing · Changchun · Chengdu · Chongqing · Fuzhou · Guangzhou
NCT05076617 on ClinicalTrials.gov ↗
Recruiting Phase 3
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Myasthenia Gravis
Janssen Research & Development, LLC · started 2021-07-15
📍 Beijing · Changchun · Changsha · Chengdu · Fuzhou · Guangzhou
NCT04951622 on ClinicalTrials.gov ↗
Active Phase 1
Study of BGB-11417 in Adult Participants With Mature B-cell Malignancies
Mature B-cell Malignancies
BeiGene · started 2021-07-05
📍 Beijing · Guangzhou · Shenzhen · Zhengzhou · Wuhan · Changsha
NCT04883957 on ClinicalTrials.gov ↗
Active Phase 2
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche · started 2020-11-27
📍 Changchun · Guangzhou · Linyi · Nanchang · Shanghai · Tianjin
NCT04576455 on ClinicalTrials.gov ↗
Active Phase 3
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Medullary Thyroid Cancer
Loxo Oncology, Inc. · started 2020-02-11
📍 Hefei · Beijing · Chongqing · Fuzhou · Lanzhou · Guangzhou
NCT04211337 on ClinicalTrials.gov ↗
Active Phase 3
A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)
Takayasu Arteritis (TAK)
AbbVie · started 2020-02-04
📍 Beijing · Guangzhou · Shenzhen · Shenyang · Shanghai
NCT04161898 on ClinicalTrials.gov ↗
Recruiting Phase 3
Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation
Rectal Cancer
Sun Yat-sen University · started 2018-11-16
📍 Guangzhou
NCT03671252 on ClinicalTrials.gov ↗
No trials match your search.

Browse by location

Beijing · 65 Guangzhou · 30 Shanghai · 28 Fuzhou · 14 Chengdu · 14 Changsha · 13 Shenzhen · 12 Hangzhou · 11 Tianjin · 10 Wuhan · 9 Chongqing · 8 Changchun · 7

Browse by condition

Breast Cancer · 5 Artificial Intelligence (AI) · 2 Healthy · 2 Aneurysmal Subarachnoid Hemorrhage · 2 Prostate Cancer · 2 Nasopharyngeal Cancinoma (NPC) · 2 Solid Tumors · 2 Healthy Participants · 2 Ischemic Stroke · 2 Wet Age-related Macular Degenerat… · 2 Plaque Psoriasis · 2 Solid Tumor · 2 Colorectal Cancer · 2 Gastric Cancer · 2 Lung Cancer (NSCLC) · 2 Pulmonary Function · 2
Cite this page

Priya Life Science (2026). Clinical Trials in China Tracker. Available at: https://priyalifescience.com/clinical-trials-china/city/guangzhou (Accessed: 12 August 2026).

Source: ClinicalTrials.gov, U.S. National Library of Medicine — studies listing at least one Chinese site, refreshed daily. Listing here is informational and not medical advice; eligibility is determined by each study team. Patients should discuss participation with their clinician.